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ABSTRACT 
Alkylated derivatives of 17-acetoxyprogesterpne were prepared in order 
to test the hypothesis that bulky groups in certain positions of the 
steroid molecule have the effect of transforming progestogens into anti- 
progestogens. These groups might exert binding influence outside the 
area occupied by progesterone itself. The compounds were tested for 
competitive affinity against trltlated progesterone and receptor from 
rabbit uterus cytosol. The low affinity of all derivatives makes it 
unlikely that they would be active as antlprogestational agents. 
A large body of accumulating evidence tends to support a unitary 
theory for the mechanism of action of steroid hormones. According to 
this theory, the steroids elicit a sequence of events starting with the 
uptake of the steroid molecule into the target cell where the steroid 
binds to a specific cytoplasmic "receptor" protein. This receptor 
proteln-steroid complex is then translocated to the nucleus where it 
binds to specific sites on the genome, thus inducing the transcription 
for a new, specific RNA. This RNA in turn, results in the ribosomal 
synthesis of new protein, which becomes the physiological expression for 
the specific steroid hormone. 
As an approach to fertility control we considered the synthesis of 
agents that would compete with the normal hormones at their sites of 
action. An antiprogestational agent might compete with progesterone 
on the progestogen-receptor proteins in target organs such as the uterus 
and the oviduct. 
*To whom inquiries should be addressed. 
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A recent review, by workers at the World Health Organization, states 
that "manipulation of receptor function offers great promise for the 
development of new contraceptive agents" (3). Attempts have been made to 
prepare potential alkylating agents of the receptor protein (4-7). Solo 
and Gardner (4,5) prepared dlazoketone derivatives of 17-hydroxyproges- 
terone and concluded that no alkylatlon of the "Clauberg receptor" had 
taken place. 
Initial efforts in this laboratory to synthesize antiprogestogens 
involved the addition of a dialkyaminoalkyl moiety to certain acylated 
derivatives of 17-hydroxyprogesterone (8). Other esters at the 17- 
position were also synthesized. All the derivatives had low affinity for 
the progestogen receptor protein, which makes it unlikely that they would 
be active as antlprogestatlonal agents. 
Our subsequent efforts were to synthesize antiprogestogens by the 
introduction of bulky groups at positions i- and 7- of the progesterone 
molecule. It is known from structure-activity studies that it is possi- 
ble to have full progestational activity in lu- and 7u- substituted pro- 
gestins (9). Some of these derivatives may exert binding influence 
outside the area occupied by progesterone itself. Incorporation of 
various functional groups in the i~- and 7u- positions might have the 
potential of reinforcing such binding to sites outside the progesterone 
binding site, and in this way, produce receptor blockade. Other work 
from this laboratory (i0) has shown that the introduction of substituents 
at the C-I or C-7 positions of androstenedlone led to agents exhibiting 
high activity as inhlbitors of estrogen biosynthesis. 
Scheme i shows the reactions used to prepared the desired products. 
Table i shows the physical and biological data for these compounds. The 
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dehydrogenation of 17-acetoxyprogesterone (I) to the A1'~-diene system 
was carried out with dlchlorodicyanoquinone (DDQ) in dioxane by a pro- 
cedure previously used for the 6-acetoxy analog (ii). The dehydrogena- 
tion to the A~'6-diene system (IV) was performed with tetrachloroqulnone 
(chloranil) as previously described in the patent literature (12). The 
addition of the mercaptans was carried out as previously described (I0) 
using the mercaptans as solvents (a,b,e,f) whenever feasible (see 
Scheme I). For the others (c,d), dioxane was used as the solvent. In 
all cases the reactions were run at 50 ° for 48 hrs. usually under a 
nitrogen atmosphere. One of the mercaptans (~-(N,N-diethylamlno)- 
thiophenol) had to be synthesized as previously reported (13). 
Addition at C-7 proceeded faster and in higher yields than at C-I. This 
was expected since the 7- position was known to be less hindered (14). 
The assignment of e- configuration to the i-- and 7- substituents is in 
accordance with the stereochemistry of other products obtained by similar 
reaction mechanisms (15,16). 
The relative affinities shown in Table I clearly indicate that the 
introduction of bulky substituents at the i- and 7- positions decrease 
binding affinity markedly. The only compound with relatively high 
affinity (Ve) has a butyl side chain instead of the bulky phenyl rings 
(Va, b, c, d) or more polar ester moiety (Vf). Substituents at the l- 
position (Ilia, b) decrease affinity by approximately an order of magni- 
tude more than substituents at the 7- position (Va, b). At the 7- 
position, introduction of a dialkylamino moiety on the phenyl ring (Vc) 
decreases affinity by an order of magnitude over the corresponding 
compound with an unsubstltuted phenyl ring (Va). 
The structure-activity studies at the 7- position are in agreement 
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with the results obtained by Lee et al. by QSAR studies (17). These 
showed the absence of a hydrophobic pocket at the 7- position of the 
progesterone molecule when binding to a progestogen receptor. 
EXPERIMENTAL SECTION 
The procedures given in this section are representative for each 
of the analogous compounds presented in Table I. The melting points 
which are corrected, were taken on a Thomas-Hoover (capillary tube) 
apparatus. Analyses were performed by Midwest Microlab, Ltd., Indiana- 
polis, Indiana. Uv spectra were obtained with a Beckman DK-2A 
spectrophotometer. Optical rotations were obtained with a Perkin Elmer 
141 polarimeter. Ir spectra were obtained with a Perkin Elmer 337 
spectrophotometer. Nmr spectra were obtained with a A-60A spectrometer 
(Me~SI or DSS). Spectra were consistent with structures shown in Table ] 
17-Acetoxypregna-!,4-diene-3,20-dipne (II). A solution of 17-acetoxy- 
pregn-4-ene-3,20-dlone (I) (i g, 2.68 mmol) and 2,3-dlchloro-5,6- 
dicyanobenzoquinone (0.92 g, 4.05 mmol) In dioxane (40 ml) was refluxed 
for 16 hr and then cooled. The precipitated hydroquinone was filtered 
and the solvent from the filtrate was removed under reduced'pressure. 
The resultant dark solid was chromatographed over activated magnesium 
silicate. Elutlon wlth benzene-CHC£3 afforded a white solid (0.61 g, 
61%): mp 222-24 ° (lit 11 233-35°). 
17-Acetoxypregna-4,6-diene-3,20-dione (IV). A solution of 17-acetoxy- 
pregn-4-ene-3,20-dione (I) (i0 g, 26.8 mmol) and tetrachloroquinone 
(6.9 g, 28.1 mmol) in glacial HOAc (80 ml) and toluene (20 ml) was 
refluxed for 30 min and then cooled. The precipitated hydroquinone was 
filtered and the solvent from the filtrate was removed under reduced 
pressure. Recrystallizatlon from acetone afforded pure product: 
mp 223-28 ° (lit 12 224-28o). 
General methods for Michael additions to A 1,~- and A~,6-ketopregnanes. 
Method A. 17-Acetoxy-l~-phenylthiopregn-4-ene-3,20-dione (Ilia). To a 
solution of II (0.5 g, 1.35 mmol) in thiophenol (6 ml) was added Na 
metal (25 mg, 1.08 mmol). The mixture was stirred at 50 ° for 46 hr 
under N2 and poured into ice-H20, acidified with dil HC£ and extracted 
with CHC£3. The organic layer was washed with H20 and dried (NazSO~). 
The solvent was removed under reduced pressure to afford an oily residu 
which was chromatographed over silica gel. Elution with hexane-CHC£3 
2:3 afforded a white solid. Recrystallization from acetone afforded 
pure product (0.50 g, 77%): mp 209-11°; [mID + 10"2° (~ 0.5, MeOH); 
uv lmax (EtOH) 243 nm (e 15,500), 216 (16,300); ir 1735, 1710, 1670, 
1610 cm-1; pmr ~ 0.68 (s, 3H, CIB-H's), 1.20 (s, C19-H's), 2.06 (s, 3H, 
COOCH3), 2.15 (s, 3H, C21-H's), 3.56 (m, CIe-H), 5.77 (s, IH, C~-H), 
7.00-7.73 (m, 5H, aromatic). 
Anal. Calcd for C29H360~S: C, 72.47; H, 7.55. Found: C, 72.54; 
H, 7.71. 
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Method B. 17-Acetoxy-7e-(p-methoxyphenylthio)pregn-4-ene-3,20-dione (Vd). 
To a solution of IV (0.5 g, 1.35 mmol) in dloxane (5 ml) was added p- 
methoxybenzenethiol (2 g, 14.2 mmol) and Na metal (25 mg, 1.08 mmol). 
The mixture was stirred at 50 ° for 5 days and worked up as described for 
Ilia. Chromatography over silica gel and recrystallizatlon from acetone 
afforded a white solid (0.48 g, 69%): mp 216-18°; [e] D - 85.8 ° (c 0.5, 
MeOH); uv %max (EtOH) 231 (e 22,000); ir 1735, 1710, 1670, 1590 cm-i: 
pmr ~ 0.70 (s, 3H, C18-H's), 1.23 (s, 3H, C19-H's), 2.11 (s, 3H, COOCH3), 
2.20 (s, 3H, C21-H's), 3.43 (m, IH, CTe-H), 3.90 (s, 3H, OCH3), 5.88 
(s, IH, C~-H), 6.77-7.78 (m, 4H, aromatic). 
Anal. Calcd for Cs0H3805S: C, 70.56; H, 7.60. Found: C, 70.28; 
H, 7,60. 
Competitive binding assay for progestogen-receptor affinity. Each sub- 
stance was tested for competitive affinity against trltium-labelled 
progesterone-3H (57 Ci/mmol, New England Nuclear, Boston, Mass.) and 
receptor from rabbit uterus cytosol (18). A series of test tubes were 
prepared with 0.5 ml buffer (10% glycerol in 0.01 M Tris, pH 7.4, with 
0.015 M EDTA and 0.25 M sucrose). The appropriate amounts of unlabelled 
competitors and labelled progesterone (3 x 10 -I° M) were dissolved in 
this buffer and 25 ~i of uterine cytosol was added. The tubes were 
incubated for 16-18 hours at +4 ° C. 3H-Progesterone binding was meas- 
ured by absorption. Every substance was run in at least 4 different 
concentrations in 3-fold dilution steps. A standard curve with un- 
labelled progesterone, concentrations between 10-I°-10 -8 M, was run at 
each experimental occasion. All substances were assayed at least twice. 
The percentage inhibition was plotted against log concentration of 
competitor and the point of 50% competition was used for potency com- 
parison. In Table i, the competitive potencies on a molar basis are 
given relative to progesterone (= i). 
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